dalteparin has been researched along with Cardiac Arrest, Sudden in 6 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 9.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 5.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| White, HD | 1 |
| Braunwald, E | 2 |
| Murphy, SA | 1 |
| Jacob, AJ | 1 |
| Gotcheva, N | 1 |
| Polonetsky, L | 1 |
| Antman, EM | 2 |
| Scirica, BM | 1 |
| Morrow, DA | 1 |
| Sadowski, Z | 1 |
| Ruda, M | 1 |
| Nicolau, JC | 1 |
| Giugliano, RP | 1 |
| Wiviott, SD | 1 |
| Sabatine, MS | 1 |
| Shui, A | 1 |
| Fox, KA | 2 |
| Bassand, JP | 1 |
| Mehta, SR | 1 |
| Wallentin, L | 1 |
| Theroux, P | 1 |
| Piegas, LS | 1 |
| Valentin, V | 1 |
| Moccetti, T | 1 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Yusuf, S | 1 |
| Hilpert, U | 1 |
| Arnheim, K | 1 |
2 reviews available for dalteparin and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Topics: Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Death, Sudden, Cardiac; Enox | 1999 |
[Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease].
Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Death, Sudden, Ca | 2000 |
3 trials available for dalteparin and Cardiac Arrest, Sudden
1 other study available for dalteparin and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Care for life. Central is the patient.
Topics: Angina, Unstable; Anticoagulants; Awards and Prizes; Death, Sudden, Cardiac; Enoxaparin; Germany; Hu | 2000 |